Scalper1 News
Specialty drugmaker Allergan (AGN) reported solid Q3 results and raised its guidance Monday, as hostile suitor Valeant Pharmaceuticals International (VRX) said that it might raise its bid for the company again. Allergan’s Q3 earnings rose 45% over the year-earlier quarter to $1.78 a share, excluding one-time items. The result was at the high end of the guidance of $1.76 to $1.78 that Allergan gave on Oct. 9, though analysts’ consensus was still Scalper1 News
Scalper1 News